Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.34 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.34 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.34 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12262375 | 0.82 | NPSR1 (0.36) | FLT3PRKCDCAMK2BCAMK2GCAMK2D | |
| SCHEMBL1902227 | 0.77 | CA1 (0.41) | FLT3PRKCDCAMK2BCAMK2GCAMK2D | |
| SCHEMBL12640263 | 0.68 | ALDH1A1 (0.32) | — | |
| SCHEMBL12640264 | 0.68 | KDM4E (0.35) | — | |
| SCHEMBL3739611 | 0.67 | NLRP3 (0.36) | — | |
| SCHEMBL2854701 | 0.64 | TLR8 (0.62) | — | |
| SCHEMBL1897611 | 0.60 | TLR8 (0.39) | FLT3PRKCDCAMK2BCAMK2GCAMK2D | |
| SCHEMBL1897612 | 0.60 | TLR8 (0.39) | FLT3PRKCDCAMK2BCAMK2GCAMK2D | |
| SCHEMBL10651511 | 0.60 | LMNA (0.58) | — | |
| SCHEMBL3393781 | 0.60 | LMNA (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247408-B2 | Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer | EXELIXIS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8044062-B2 | Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha | EXELIXIS, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20100209420-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA | EXELIXIS, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100150827-A1 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2010-06-17 | — | — | US | disclosed |
| US-20090270430-A1 | Pyridopyrimidinone Inhibitors of Pl3Kalpha | EXELIXIX, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | EXELIXIS, INC (US) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | PIK3CA, PIK3CD, PIK3CB | FLT3 371/4885PRKCD 314/4885CAMK2B 1094/4885 |
| US-20090270430-A1 | Pyridopyrimidinone Inhibitors of Pl3Kalpha | PLK3, PLK4, PLK2 | FLT3 339/4885PRKCD 609/4885CAMK2B 1785/4885 |
| US-20100209420-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA | TP53, PHKG1, TNNI3K | FLT3 621/4885PRKCD 410/4885CAMK2B 1045/4885 |
| US-20100150827-A1 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER | PIK3CA, CDKN1A, PIK3CD | FLT3 621/4885PRKCD 190/4885CAMK2B 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.